Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma

Purpose We aimed to investigate the recommended dose for the combination of TSU-68, a multiple-receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2 and platelet-derived growth factor receptor-β, and S-1, an oral fluoropyrimidine, in patients with advanced hepato...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Ikeda, Masafumi, Shiina, Shuichiro, Nakachi, Kohei, Mitsunaga, Shuichi, Shimizu, Satoshi, Kojima, Yasushi, Ueno, Hideki, Morizane, Chigusa, Kondo, Shunsuke, Sakamoto, Yasunari, Asaoka, Yoshinari, Tateishi, Ryosuke, Koike, Kazuhiko, Arioka, Hitoshi, Okusaka, Takuji
Format: Artigo
Jezik:Inglês
Izdano: Springer US 2014
Teme:
Phase I Studies
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4169869/
https://ncbi.nlm.nih.gov/pubmed/24829073
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0109-2
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items